MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ALKS

ALKS

Alkermes plc

$52.53
-2.55
 (-4.63%)
Exchange:  NASDAQ
Market Cap:  8.755B
Shares Outstanding:  16.531M
Delayed data
Calculate ALKS Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Richard F. Pops
Full Time Employees:  2095
Address: 
Connaught House
Dublin
D04 C5Y6
IE
Website:  http://www.alkermes.com
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/05 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,663,4051,557,6321,475,899
Gross Profit1,410,3681,312,3011,279,442
EBITDA519,478494,861330,892
Operating Income414,122420,636253,956
Net Income355,757367,070241,664

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,136,2232,055,5672,486,993
Total Liabilities933,537590,590667,698
Total Stockholders Equity1,202,6861,464,9771,819,295
Total Debt372,18575,53869,999
Cash and Cash Equivalents457,469291,146588,360

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow401,353439,124520.799
Capital Expenditure-48,048-33,4840
Free Cash Flow353,305405,640520.799
Net Income355,757367,070241,664
Net Change in Cash164,996-166,323828.700

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)2,591,321.564Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)2,804,585.411Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)2,663,942.800Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)548,980.441Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)594,161.125Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)564,365.501Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)578,530.316Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)640,951.727Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)599,786.872Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,193,989.355Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,292,253.796Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,227,450.653Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)3.550Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)3.800Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)3.430Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)6Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
1.558B  ?P/S
 (TTM)
: 
5.88
?Net Income
 (TTM)
: 
367.07M  ?P/E
 (TTM)
: 
59.23
?Enterprise Value
 (TTM)
: 
10.411B  ?EV/FCF
 (TTM)
: 
46.94
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.09  ?ROIC
 (TTM)
: 
0.04
?Net Debt
 (TTM)
: 
-676130000  ?Debt/Equity
 (TTM)
: 
0.9
?P/B
 (TTM)
: 
5.23  ?Current Ratio
 (TTM)
: 
2.27

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates ALKS intrinsic value between $30.98 – $35.28 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about ALKS valuation

Is Alkermes plc (ALKS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Alkermes plc (ALKS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ALKS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ALKS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ALKS’s P/E ratio?

You can see ALKS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ALKS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ALKS a good long-term investment?

Whether ALKS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ALKS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-4.63
MARKETSnap

Trading Metrics:

Open: 53.92   Previous Close: 55.08
Day Low: 52.27   Day High: 54.45
Year Low: 25.17   Year High: 55.28
Price Avg 50: 39.51   Price Avg 200: 32.71
Volume: 2.327M   Average Volume: 2.363M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
19-06-2026 15:49
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
17-06-2026 16:15
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
10-06-2026 14:09
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tells Investors
09-06-2026 19:57
Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tells Investors
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles
12-05-2026 14:27
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles
Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results
06-05-2026 13:54
Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read